While this provided excellent specificity and high sensitivity for classical PTC, it does not cover the mutational spectrum of FVPTC, follicular thyroid carcinoma (FTC), and some low-risk neoplasms, which are frequently associated with RAS family mutations or, in the case of more aggressive tumors, TERT promoter mutations. This evidence concerns the gene TERT and thyroid cancer, nonmedullary, 2.